Fetal methotrexate syndrome: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{SI}} {{CMG}} {{AE}} {{KD}} '''''Synonyms and keywords:''''' Aminopterin embryopathy syndrome, aminopterin fetopathy syndrome, aminopterin syndrome, fetal methot...") |
No edit summary |
||
Line 3: | Line 3: | ||
{{CMG}} {{AE}} {{KD}} | {{CMG}} {{AE}} {{KD}} | ||
'''''Synonyms and keywords:''''' Aminopterin embryopathy syndrome, aminopterin fetopathy syndrome, aminopterin | '''''Synonyms and keywords:''''' Aminopterin embryopathy syndrome, aminopterin fetopathy syndrome, aminopterin syndrome | ||
==Overview== | ==Overview== |
Revision as of 14:51, 31 July 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Kalsang Dolma, M.B.B.S.[2]
Synonyms and keywords: Aminopterin embryopathy syndrome, aminopterin fetopathy syndrome, aminopterin syndrome
Overview
Congenital abnormalities have been documented with methotrexate and aminopterin, and collectively their teratogenic effects have become known as the fetal aminopterin syndrome.
Diagnosis
History
A directed history should be obtained to ascertain prenatal exposure of methotrexate and aminopterin.
Physical Examination
Head
- Craniosynostosis - some or all of the sutures in the skull of an infant or child close too early, causing problems with normal brain and skull growth.